scispace - formally typeset
C

Chee Fu Yung

Researcher at Boston Children's Hospital

Publications -  96
Citations -  2307

Chee Fu Yung is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Medicine & Vaccination. The author has an hindex of 19, co-authored 79 publications receiving 1630 citations. Previous affiliations of Chee Fu Yung include Health Protection Agency & Tan Tock Seng Hospital.

Papers
More filters
Journal ArticleDOI

A Well Infant With Coronavirus Disease 2019 With High Viral Load.

TL;DR: This case highlights the difficulties in establishing the true incidence of COVID-19, as asymptomatic individuals can excrete the virus, and patients may play important roles in human-to-human transmission in the community.
Journal ArticleDOI

Effectiveness of Masks and Respirators Against Respiratory Infections in Healthcare Workers: A Systematic Review and Meta-Analysis.

TL;DR: Evidence for a protective effect of facemasks and respirators against clinical respiratory infection among healthcare workers, and limited evidence for superiority of respirators is found.
Journal ArticleDOI

Dengue Serotype-Specific Differences in Clinical Manifestation, Laboratory Parameters and Risk of Severe Disease in Adults, Singapore

TL;DR: Cases infected with DENV-1 were more likely to present with red eyes whereas presence of joint pain and lower platelet count was associated withDENV-2 cases, and Infecting dengue serotype and possibly genotype may play an important role in disease severity among adult d Dengue patients in Singapore.
Journal ArticleDOI

Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis

You-yi Li, +120 more
- 01 May 2022 - 
TL;DR: This systematic analysis aims to update RSV-associated acute lower respiratory infection morbidity and mortality at global, regional, and national levels in children aged 0–60 months for 2019, with focus on overall mortality and narrower infant age groups that are targeted by RSV prophylactics in development.